首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes.
【24h】

Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes.

机译:氨磷汀有可能在低危和中危1型骨髓增生异常综合症的个别患者中引起血液学反应并减慢疾病进展。

获取原文
获取原文并翻译 | 示例
           

摘要

Myelodysplastic syndromes (MDS) are characterized by hypercellular bone marrow, peripheral cytopenia and an increased rate of intramedullary apoptosis. Oxidative stress is known as an important factor that leads to apoptosis in MDS. Thus, amifostine was investigated in a randomized, multicentre phase II-study (n = 44 pts.; 22 amifostine, 22 best supportive care). We found an overall haematologic response rate of 18%. One patient developed a complete and persisting haematologic remission. Haematologic progression rate was 46% in the treatment group and 64% in the control group. We conclude that amifostine has the potential to induce haematologic response in individual patients suffering from MDS.
机译:骨髓增生异常综合症(MDS)的特征是高细胞骨髓,外周血细胞减少和髓内凋亡率增加。氧化应激是导致MDS凋亡的重要因素。因此,在一项随机,多中心的II期研究中对氨磷汀进行了研究(n = 44分; 22个氨磷汀,22种最佳支持治疗)。我们发现总体血液学反应率为18%。一名患者出现了完全且持续的血液学缓解。治疗组的血液学进展率为46%,对照组为64%。我们得出的结论是,氨磷汀在患有MDS的个别患者中具有诱导血液学反应的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号